Co-Authors
This is a "connection" page, showing publications co-authored by Dennis Burton and David Nemazee.
Connection Strength
0.858
-
A Rapid Assay for SARS-CoV-2 Neutralizing Antibodies That Is Insensitive to Antiretroviral Drugs. J Immunol. 2021 07 01; 207(1):344-351.
Score: 0.238
-
Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020 08 21; 369(6506):956-963.
Score: 0.222
-
Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. Science. 2021 08 13; 373(6556):818-823.
Score: 0.059
-
Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. Nat Commun. 2021 05 19; 12(1):2938.
Score: 0.059
-
A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. Cell Host Microbe. 2021 05 12; 29(5):806-818.e6.
Score: 0.059
-
Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science. 2021 02 19; 371(6531):823-829.
Score: 0.058
-
A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody. PLoS Pathog. 2020 12; 16(12):e1009089.
Score: 0.057
-
Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science. 2020 08 07; 369(6504):731-736.
Score: 0.055
-
HIV-1 vaccine design through minimizing envelope metastability. Sci Adv. 2018 11; 4(11):eaau6769.
Score: 0.050